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Antifungal activityAbstract In this study a series of new mannich bases were synthesized and characterized by ele-
mental and spectral (IR, 1H NMR, 13C NMR) studies. All the synthesized compounds were eval-
uated for their antimicrobial activity by broth dilution method against two Gram negative strains
(Escherichia coli and Pseudomonas aeruginosa), two Gram positive strains (Bacillus subtilis and
Staphylococcus aureus) and fungal strain (Candida albicans and Aspergillus niger). Preliminary phar-
macological evaluation revealed that the compounds (3f, 3i, 3j, and 3k) showed good activity against
these strains. The result demonstrates the potential and importance of developing new mannich
bases which would be effective against resistant bacterial and fungal strain.
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The incidence of microbial infection has increased on alarm-
ing levels over the world as a result of antimicrobial resis-
tance in past 25 years. The rapid development of resistanceto existing antibacterial and antifungal drugs posses a major
threat to public health and it creates a serious challenge to
the scientiﬁc community. In addition, the treatment of infec-
tious diseases is more complicated in immuno-suppressed
patients, such as those infected with the HIV, undergoing
anticancer therapy and organ transplants. Consequently,
there is a vital need for the development of new antimicro-
bial agents having potent activity against the resistant
microorganisms (Koca et al., 2005; Bonde and Gaikwad,
2004; Yu and Huiyuan, 2002; Ram, 1988). Hydrazones have
been reported to posses, antimicrobial (Rollas et al., 2002),
antitubercular (Imramovsky et al., 2007; Janin, 2007),
antileprotic (Buuhoi et al., 1956), anticonvulsant (Dimmock
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(Salgin-Goksen et al., 2007; Kalsi et al., 1990), antiplatelet
(Silva et al., 2004), anticancer (Savini et al., 2004; Bijev,
2006) and antiviral (Abdel-Aal et al., 2006) activity.
Inspired by the above facts and in continuation of our
ongoing research program in the ﬁeld of synthesis and anti-
microbial activity of medicinally important compounds
(Deep et al., 2010a, b; Madhukar et al., 2009; Kumar et
al., 2010), we hereby report the synthesis the novel derivatives
of isoniazid and evaluated them for antimicrobial activity.
2. Materials and methods
Melting points of the synthesized compounds were deter-
mined in open-glass capillaries on Stuart SMP10 melting
point apparatus and were uncorrected. The purity of the
compounds was checked by thin layer chromatography
(TLC). Silica gel plates kiesel gel 0.25 mm, 60G F 254,
precoated sheets obtained from Merck, Darmstadt (Ger-
many) were used for TLC and the spots were visualized
by iodine vapors/ultraviolet light as visualizing agent.
The IR spectra (t, cm1) were obtained with a Perkin-
Elmer 1600 FTIR spectrometer in KBr pellets. 1H NMR
spectra (d, ppm) were recorded in DMSO-d6 solutions on
a Varian-Mercury 300 MHz spectrometer using tetrameth-
ylsilane as the internal reference. 13C NMR spectra were
recorded on in DMSO-d6 solutions on a Bruker Avance
II 400 spectrometer at 400 MHz using tetramethylsilane
as the internal reference. Elemental analyses were per-
formed on an ECS 4010 Elemental Combustion System.
The necessary chemicals were purchased from Loba Che-
mie, Fluka and Aldrich.
3. Chemistry
The synthesis of target compounds was carried outline in
synthetic scheme (Scheme 1). Compounds 3a–3k was readilyN C
O
NH NH2 +
C2H5OH
H2N
O
H
     Isoniazid               2-Aminobenzaldehyde         2-A
(1)                                       (2)
Scheme 1 Synthetic pathway for theprepared in good yields and purity. Equimolar quantity of
2-aminobenzaldehyde (2) and isoniazid (1) in 15 ml of absolute
ethanol was reﬂuxed for 7 h to form acid hydrazone. The
completion of reaction was conﬁrmed by thin layer
chromatography (TLC). Then 2-aminobenzylidene ison-
icotinohydrazide (3a) along with formaldehyde and substituted
secondary amines were reﬂuxed for 34–42 h in presence of
50 ml of super dry ethanol (method of preparation of dry eth-
anol: take 1 l of ethanol and add 25 g of magnesium metals.
Reﬂux until the metal is consumed (add a few drops of chloro-
form if it does not start to get cloudy). It will take a good 24 h
to convert the metal to magnesium ethoxide. Then just distill
the ethanol off. It will be very dry) and the pH was adjusted
to 4 with hydrochloric acid. The types of substituted secondary
amines are speciﬁed in Table 1. The synthesized novel mannich
bases were characterized on the basis of the spectral and
analytical studies.
3.1. Synthesis of 2-aminobenzylidene isonicotinohydrazide
A mixture of 2-aminobenzaldehyde (1.21 g, 0.01 mol) and iso-
niazid (1.37 g, 0.01 mol) in 15 ml of super dry ethanol was
reﬂuxed for 7 h. The completion of reaction was conﬁrmed
by TLC. The reaction mixture was then poured in ice cold
water and the precipitate obtained was ﬁltered and dried in
oven at low temperature. The product was recrystallised from
absolute ethanol.
3.2. N-(2-Aminobenzylidine)isonicotinohydrazide (3a)
Yield 58%;m.p. 205–208 C; IR (KBr; cm1): 3465, 3275, 3181,
2985, 2857, 2849, 1674, 1648, 1557, 1085. 1H NMR (300 MHz,
DMSO-d6, d ppm): 11.95 (s, 1H, –NH–N‚), 8.65 (d, 2H, pyri-
dine, J= 4.1 Hz), 8.37 (s, 1H, –N‚C–H), 7.94 (d, 2H, pyridine,
J= 3.7 Hz), 7.69 (d, 2H, benzylidene, J=8.2 Hz), 7.37 (d, 2H,
benzylidene, J= 7.8 Hz), 5.42 (s, 2H,NH2,D2Oexchangeable);
13CNMR(400 MHz,DMSO-d6, dppm): 163.54, 161.18, 149.83,N C
O
NH N C
H
minobenzylidene isonicotinohydrazide                         
(3a) 
                                           R                                       
              HCHO      HN  
                                            R'
N C
O
NH N C
H
N
R
R'
   Substituted Mannich bases (3b-3k)  
H2N
H2N
formation of the title compounds.
Table 1 Physical data of synthesized mannich bases.
N C
O
NH N C
H
NH2 R
.Compounds R Molecular formulae Yield (%) Mp (C)
3b –N(CH3)2 C16H29N5O 48 222–225
3c –N(C2H5)2 C18H23N5O 52 215–218
3d –N(C3H7)2 C20H27N5O 45 210–213
3e –N(C4H9)2 C22H31N5O 48 208–211
3f –N(C6H5)2 C26H23N5O 53 196–199
3g N C19H23N5O 57 188–190
3h N C18H21N5O 55 198–201
3i N O C18H21N5O2 42 219–222
3j N NH C18H22N6O 47 206–209
3k N NCH3 C19H24N6O 46 211–214
668 M. Malhotra et al.143.37, 139.85, 132.68, 130.15, 122.85, 121.23, 118.59, 115.84.
Anal. Calcd. for C13H11N3O2: C, 64.72; H, 4.60; N, 17.42.
Found: C, 64.78; H, 4.62; N, 17.34.
3.3. Synthesis of substituted mannich bases (3b–3k)
The 2-aminobenzylidene isonicotinohydrazide (576 mg, 0.0024
mol) along with (0.1 ml, 0.0036 mol) of formaldehyde and
(0.0024 mol) of substituted secondary amines was placed in
100 ml round bottomed ﬂask to which 50 ml of super dry ethanol
was added and the pH was adjusted to 4 with hydrochloric acid
and reﬂuxed for 28–33 h. The completion of reaction was con-
ﬁrmedbyTLC.The reactionmixturewas thenpoured intobeaker
and concentrated on water bath. The reaction mixture was
allowed to cool at room temperature and then in which diethyl
etherwas added.The reactionmixturewaskept for 3–5 h in refrig-
erator and ﬁltered and washed with n-hexane. The products were
recrystallised from absolute ethanol (Sriram et al., 2005).
3.4. N-3-((Dimethyamino) methyl)-2-aminobenzylidene)-
isonicotinohydrazide (3b)
IR (KBr; cm1): 3348, 3265, 3185, 2965, 2863, 2842, 1674,
1645, 1566, 1082. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.95 (s, 1H, –NH–N‚), 8.69 (d, 2H, pyridine, J= 4.2 Hz),
8.46 (s, 1H, –N‚C–H), 7.89 (d, 2H, pyridine, J= 3.8 Hz),
7.72 (d, 1H, benzylidene, J= 3.2 Hz), 7.24 (t, 1H, benzyli-
dene), 4.25 (s, 2H, NH2, D2O exchangeable), 3.59 (s, 2H,Ar–CH2–N), 2.18 (s, 6H, N–2CH3);
13C NMR (400 MHz,
DMSO-d6, d ppm): 163.59, 149.62, 148.57, 143.29, 139.87,
132.54, 128.52, 124.57, 122.49, 118.72, 114.87, 56.64, 46.89.
Anal. Calcd. for C16H19N5O: C, 64.63; H, 6.44; N, 23.55.
Found: C, 64.68; H, 6.47; N, 23.47.
3.5. N-3-((Diethyamino) methyl)-2-aminobenzylidene)-
isonicotinohydrazide (3c)
IR (KBr; cm1): 3445, 3268, 3175, 2974, 2864, 2843, 1676,
1648, 1565, 1074. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.92 (s, 1H, –NH–N‚), 8.54 (d, 2H, pyridine, J= 4.2 Hz),
8.52 (s, 1H, –N‚C–H), 7.85 (d, 2H, pyridine, J= 3.9 Hz),
7.65 (d, 2H, benzylidene, J= 3.2 Hz), 7.12 (t, 1H, benzyli-
dene), 4.11 (s, 2H, NH2, D2O exchangeable), 3.55 (s, 2H,
Ar–CH2–N), 2.25 (m, 4H, N–2CH2), 1.18 (m, 6H, 2CH3);
13C NMR (400 MHz, DMSO-d6, d ppm): 163.29, 149.85,
148.24, 143.13, 139.81, 132.19, 128.72, 124.59, 122.57, 118.53,
114.71, 52.17, 49.28, 14.75. Anal. Calcd. for C18H23N5O: C,
66.44; H, 7.12; N, 21.52. Found: C, 66.28; H, 7.25; N, 21.55.
3.6. N-3-((Dipropylamino)methyl)-2-aminobenzylidene)-
isonicotinohydrazide (3d)
IR (KBr; cm1): 3452, 3255, 3188, 2982, 2863, 2844, 1677, 1647,
1561, 1078. 1H NMR (300 MHz, DMSO-d6, d ppm): 11.88 (s,
1H, –NH–N‚), 8.59 (d, 2H, pyridine, J= 4.1 Hz), 8.47 (s, 1H,
–N‚C–H), 7.69 (d, 2H, pyridine, J= 3.8 Hz), 7.45 (d, 2H, ben-
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D2O exchangeable), 3.81 (s, 2H, Ar–CH2–N), 2.35 (t, 4H, N–
2CH2), 1.56 (m, 4H, 2CH2), 1.12 (m, 6H, 2CH3);
13C NMR
(400 MHz, DMSO-d6, d ppm): 163.59, 149.74, 148.12, 143.18,
139.74, 132.34, 128.59, 124.52, 122.65, 118.64, 114.79, 57.24,
52.18, 22.55, 13.72. Anal. Calcd. for C20H27N5O: C, 67.96; H,
7.70; N, 19.81. Found: C, 67.95; H, 7.64; N, 19.88.
3.7. N-3-((Dibutylamino)methyl-2-aminobenzylidene)-
isonicotinohydrazide (3e)
IR (KBr; cm1): 3452, 3292, 3178, 2971, 2864, 2845, 1668,
1644, 1558, 1072. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.85 (s, 1H, –NH–N‚), 8.55 (d, 2H, pyridine, J= 4.1 Hz),
8.49 (s, 1H, –N‚C–H), 7.85 (d, 2H, pyridine, J= 3.7 Hz),
7.78 (d, 2H, benzylidene, J= 3.2 Hz), 7.42 (t, 1H, benzyli-
dene), 4.18 (s, 2H, NH2, D2O exchangeable), 3.64 (s, 2H,
Ar–CH2–N), 2.32 (t, 4H, N–2CH2), 1.35 (m, 8H, 4CH2),
1.15 (t, 6H, 2CH3);
13C NMR (400 MHz, DMSO-d6, d ppm):
163.54, 149.45, 143.35, 139.78, 132.64, 128.55, 124.59, 122.68,
118.65, 114.88, 55.72, 52.18, 32.67, 21.15, 15.71. Anal. Calcd.
for C22H31N5O: C, 69.28; H, 8.12; N, 18.40. Found: C,
69.25; H, 8.19; N, 18.36.
3.8. N-(3((Diphenylamino)-methyl)-2-aminobenzylidene)-
isonicotinohydrazide (3f)
IR (KBr; cm1): 3446, 3269, 3185, 2967, 2859, 2842, 1674,
1645, 1549, 1074. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.95 (s, 1H, –NH–N‚), 8.69 (d, 2H, pyridine, J= 4.2 Hz),
8.52 (s, 1H, –N‚C–H), 7.85 (d, 2H, pyridine, J= 3.9 Hz),
7.89–6.92 (m, 13H, benzylidene), 4.25 (s, 2H, NH2, D2O
exchangeable), 3.78 (s, 2H, Ar–CH2–N);
13C NMR (400
MHz, DMSO-d6, d ppm): 163.18, 149.87, 148.22, 143.58,
139.65, 132.59, 128.59, 124.55, 122.78, 119.18, 117.53, 114.29,
47.81. Anal. Calcd. for C26H23N5O: C, 74.09; H, 5.50; N,
16.62. Found: C, 74.13; H, 5.55; N, 16.53.
3.9. N-(2-Amino-3-((piperidine-1-yl)methyl)benzylidene)-
isonicotinohydrazide (3g)
IR (KBr; cm1): 3458, 3294, 3175, 2984, 2862, 2844, 1678,
1648, 1555, 1077. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.78 (s, 1H, –NH–N‚), 8.58 (d, 2H, pyridine, J= 4.1 Hz),
8.45 (s, 1H, –N‚C–H), 7.88 (d, 2H, pyridine, J= 3.8 Hz),
7.75 (d, 2H, benzylidene, J= 3.1 Hz), 7.45 (t, 1H, benzyli-
dene), 4.28 (s, 2H, NH2, D2O exchangeable), 3.51 (s, 2H,
Ar–CH2–N), 2.24 (t, 4H, N–2CH2, piperidine), 1.82 (m, 6H,
3CH2, piperidine);
13C NMR (400 MHz, DMSO-d6, d ppm):
163.44, 149.65, 148.27, 143.38, 139.63, 132.54, 128.41, 124.58,
121.72, 118.64, 114.61, 55.64, 52.37, 27.18. Anal. Calcd. for
C19H23N5O: C, 67.63; H, 6.87; N, 20.67. Found: C, 67.68;
H, 6.85; N, 20.64.
3.10. N-(2-Amino-3-((pyrrolidin-1-yl)methyl)benzylidene)-
isonicotinohydrazide (3h)
IR (KBr; cm1): 3462, 3281, 3178, 2983, 2865, 2838, 1675,
1642, 1552, 1073. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.83 (s, 1H, –NH–N‚), 8.68 (d, 2H, pyridine, J= 4.1 Hz),
8.43 (s, 1H, –N‚C–H), 7.85 (d, 2H, pyridine, J= 3.9 Hz),
7.82 (d, 2H, benzylidene, J= 3.2 Hz), 7.32 (t, 1H, benzyli-dene), 4.15 (s, 2H, NH2, D2O exchangeable), 3.55 (s, 2H,
Ar–CH2–N), 2.32 (m, 4H, N–2CH2, pyrrolidine), 1.58 (m,
4H, 2CH2, pyrrolidine);
13C NMR (400 MHz, DMSO-d6, d
ppm): 163.48, 149.66, 148.28, 143.29, 139.62, 132.55, 128.54,
124.51, 122.75, 118.69, 114.64, 58.84, 52.18, 25.18. Anal.
Calcd. for C18H21N5O: C, 66.85; H, 6.55; N, 21.66. Found:
C, 66.73; H, 6.72; N, 21.61.
3.11. N-(2-Amino-3-((morpholinomethyl)benzylidene)-
isonicotinohydrazide (3i)
IR (KBr; cm1): 3465, 3278, 3172, 2985, 2861, 2847, 1674,
1644, 1551, 1085. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.89 (s, 1H, –NH–N‚), 8.65 (d, 2H, pyridine, J= 4.2 Hz),
8.37 (s, 1H, –N‚C–H), 7.85 (d, 2H, pyridine, J= 3.8 Hz),
7.81 (d, 2H, benzylidene, J= 3.1 Hz), 7.35 (t, 1H, benzyli-
dene), 4.18 (s, 2H, NH2, D2O exchangeable), 3.58 (s, 2H,
Ar–CH2–N), 3.42 (m, 4H, O–2CH2, morpholine), 2.35 (t,
4H, N–2CH2, morpholine);
13C NMR (400 MHz, DMSO-d6,
d ppm): 163.65, 149.84, 148.15, 143.35, 139.68, 132.47,
128.43, 122.64, 118.74, 114.72, 68.52, 55.71, 52.18. Anal.
Calcd. for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64. Found:
C, 63.84; H, 6.13; N, 20.61.
3.12. N-(2-Amino-3-((piperazin-1-yl) methyl)benzylidene)-
isonicotinohydrazide (3j)
IR (KBr; cm1): 3462, 3274, 3171, 2988, 2862, 2843, 1672,
1641, 1554, 1082. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.88 (s, 1H, –NH–N‚), 8.68 (d, 2H, pyridine, J= 4.1 Hz),
8.35 (s, 1H, –N‚C–H), 7.82 (d, 2H, pyridine, J= 3.7 Hz),
7.84 (d, 2H, benzylidene, J= 3.2 Hz), 7.29 (t, 1H, benzyli-
dene), 4.15 (s, 2H, NH2, D2O exchangeable), 3.55 (s, 2H,
Ar–CH2–N), 2.65–2.48 (m, 8H, 4CH2, piperazine);
13C NMR
(400 MHz, DMSO-d6, d ppm): 163.51, 149.86, 148.27,
143.49, 139.67, 132.58, 128.38, 122.49, 118.63, 114.78, 55.81,
52.77, 47.18. Anal. Calcd. for C18H22N6O: C, 63.89; H, 6.55;
N, 24.83. Found: C, 63.72; H, 6.69; N, 24.86.
3.13. N-(2-Amino-3-((4-methylpiperazin-1-yl)methyl)-
benzylidene)isonicotinohydrazide (3k)
IR (KBr; cm1): 3462, 3274, 3175, 2982, 2863, 2842, 1675,
1643, 1555, 1088. 1H NMR (300 MHz, DMSO-d6, d ppm):
11.93 (s, 1H, –NH–N‚), 8.67 (d, 2H, pyridine, J= 4.2 Hz),
8.19 (s, 1H, –N‚C–H), 7.83 (d, 2H, pyridine, J= 3.7 Hz),
7.66 (d, 2H, benzylidene, J= 3.2 Hz), 7.18 (t, 1H, benzyli-
dene), 4.32 (s, 2H, NH2, D2O exchangeable), 3.72 (s, 2H,
Ar–CH2–N), 2.45 (m, 8H, 4CH2, piperazine), 2.13 (s, 3H,
CH3);
13C NMR (400 MHz, DMSO-d6, d ppm): 163.39,
149.87, 148.11, 143.37, 139.61, 132.39, 128.45, 122.81, 118.24,
114.67, 58.22, 53.14, 52.19, 44.39. Anal. Calcd. for
C19H24N6O: C, 64.75; H, 6.86; N, 23.85. Found: C, 64.67;
H, 6.81; N, 23.98.4. Antimicrobial evaluation
The synthesized compounds were evaluated for their in vitro
antimicrobial activity against Gram positive bacteria:Staphylo-
coccus aureus (MTCC 121),Bacillus subtilis (MTCC 96), Gram
negative Escherichia coli (MTCC 40), Pseudomonas aeruginosa
Table 2 Antimicrobial screening results of the tested compounds.
Compound Minimum inhibitory concentration (lg ml1)
Gram positive bacteria Gram negative bacteria Fungal strain
B. subtilis
(MTCC 96)
S. aureus
(MTCC 121)
P. aeruginosa
(MTCC 2453)
E. coli
(MTCC 40)
C. albicans
(MTCC 8184)
A. niger
(MTCC 8184)
3a 12.5 25 12.5 6.25 12.5 12.5
3b 12.5 25 3.12 6.25 25 50
3c 6.25 25 50 >100 12.5 12.5
3d 3.12 12.5 12.5 25 50 12.5
3e 25 50 12.5 6.25 3.12 12.5
3f 3.12 1.56 3.12 1.56 3.12 3.12
3g 25 50 25 12.5 12.5 50
3h 6.25 25 12.5 6.25 12.5 25
3i 1.56 3.12 3.12 3.12 1.56 3.12
3j 3.12 3.12 1.56 1.56 3.12 3.12
3k 3.12 6.25 1.56 1.56 12.5 1.56
Amoxicillin 0.15 0.15 0.25 0.15 – –
Nystatin – – – – 0.25 0.78
670 M. Malhotra et al.(MTCC 2453) and fungal strain: Candida albicans (MTCC
8184) and Aspergillus niger (MTCC 8189). Antimicrobial
activity was assessed by serial twofold dilution technique.
Amoxicillin was used as a standard drug for antibacterial activ-
ity while Nystatin was used as a standard drug for antifungal
activity. All the compounds were dissolved in dimethyl sulfox-
ide to give a concentration of 10 lg ml1. Twofold dilutions of
test and standard compounds were prepared in double strength
nutrient broth I.P. (bacteria) or Sabouraud dextrose broth
I.P. (fungi) (Pharmacopoeia, 1996). The stock solution was
serially diluted to give concentrations of 100–0.78 lg ml1 in
nutrient broth. The inoculum size was approximately
106 colony forming units (CFU/ml). The tubes were
incubated at 37 ± 1 C for 24 h (bacteria) and 25 C for
7 days (A. niger). After that, the inoculated culture tubes were
macroscopically examined for turbidity. The culture tube
showing turbidity (lower concentration) and the culture tube
showing no turbidity (higher concentration) gave the
minimum inhibitory concentration (MIC) for the compound.
The MIC for antimicrobial was given in Table 2.5. Results and discussion
In this study novel mannich bases have been synthesized and
evaluated them for antimicrobial activity. In general, IR spec-
tra of all compound 3a–3k showed absorption band at around
3465–3165, 3240–3255, 2988–2965, 2865–2838, 1678–1668,
1648–1641, 1566–1549, and 1088–1072 cm1 regions, conform-
ing the presence of NH2, NH, CH, CH2, C‚N, C‚O, C‚C,
and C–N, respectively. The 1H NMR spectra, the signals of the
respective prepared derivatives were veriﬁed on the basis of
their chemical shifts, multiplicities, and coupling constants.
The spectra of most compounds showed the characteristic
NH proton d 11.95–11.78 ppm, 1H proton of –N‚C–H at d
8.52–8.25 ppm, 4H proton of pyridine were at around d
8.89–7.65 ppm, characteristic protons of benzylidene at d
7.89–6.94 ppm, 2H proton of NH2 at d 5.42–4.11 ppm and
2H proton of Ar–CH2–N at d 3.81–3.51 ppm,
13C NMR spec-
tra of most compounds have characteristic C‚O signalsappeared at around d 163.18–163.65 ppm, pyridine d 149.87–
122.49 ppm, –N‚C–H d 143.58–143.18 ppm, benzylidene
d 161.18–114.29 ppm, Ar–CH2–N d 56.15–50.67 ppm. The
elemental analysis, IR and 1H NMR, 13C NMR spectral data
of synthesized compounds were found in agreement with the
assigned molecular structure. Among the synthesized deriva-
tives, compounds (3f, 3i, 3j, and 3k) were the most active deriv-
atives against these strains as compared to the standard drugs.
So, it was concluded that the presence of diphenyl amine, mor-
pholine, piperazine and N-methyl piperazine moiety besides
pyridine ring was found to be essential for their high antibac-
terial and antifungal activity. It was also concluded from the
results that antimicrobial activity increases with increase in
chain length from dimethyl amine to dibutyl amine. So, the sig-
niﬁcant antimicrobial activity of compound may be due to the
presence of diphenyl amine, morpholine, piperazine and N-
methyl piperazine moiety in addition to hydrazide functional
group.
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